Table 2
Choice of tissue for quality control of PSA and PSAP immunohistochemistry
| Tissue | Optimisation of antibody dilutions | External positive control | ||
|---|---|---|---|---|
| UK laboratories N (%) | Non-UK laboratories N (%) | UK laboratories N (%) | Non-UK laboratories N (%) | |
| PC, prostate cancer; PSA, prostate specific antigen; PSAP, prostate specific acid phosphatase. | ||||
| Not indicated | 11 (8%) | 7 (8%) | 5 (4%) | 6 (7%) |
| None | 0 | 2 (2%) | 11 (8%) | 6 (7%) |
| Benign prostate | 84 (63%) | 65 (75%) | 82 (62%) | 67 (77%) |
| Benign prostate + well differentiated PC | 14 (11%) | 4 (5%) | 10 (8%) | 2 (2%) |
| Well differentiated PC | 15 (11%) | 5 (6%) | 20 (15%) | 5 (6%) |
| Benign prostate + poorly differentiated PC | 2 (2%) | 1 (1%) | 2 (2%) | 0 |
| Well differentiated PC + poorly differentiated PC | 1 (1%) | 0 | 1 (1%) | 0 |
| Poorly differentiated PC | 2 (2%) | 0 | 1 (1%) | 0 |
| Benign prostate + well differentiated PC + poorly differentiated PC | 4 (3%) | 3 (3%) | 1 (1%) | 1 (1%) |
